Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of Class A common stock and restricted stock units (RSUs) for 105,125 shares of Class A common stock to sixteen (16) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employme...
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 51,500 shares of Class A common stock and restricted stock units (RSUs) for 25,750 shares of Class A common stock to nine (9) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in...
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference, which is taking place in Boston, MA from March 3 – 5, 2025. The management team will also participate in one-on-one in...
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval planned in 2H 2025Expanded atacicept clinical development program in multiple autoimmune kidney diseases proceeding in 2025Strengthened balance sheet to support clinical pipeline development, planned FDA submission, and potential 2026 commercial launch of atacicept for the treatment of IgAN BRIS...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on February 8, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 157,750 shares of Class A common stock and restricted stock units (RSUs) for 78,875 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ empl...
OneWater Marine Inc. Announces Fiscal First Quarter Results Executing on Strategic Approach for Driving Sales and Managing Inventory Fiscal First Quarter 2025 Highlights Revenue increased 3% to $376 millionSame-store sales increased 4%, including an increase in units soldGross profit margin of 22.4%, impacted by exiting brandsGAAP net loss of $14 million, or $(0.81) per diluted share and adjusted diluted loss per share1 of $(0.54)Adjusted EBITDA1 of $2 million BUFORD, Ga., Jan. 30, 2025 (GLOBE NEWSWIRE) -- OneWater Marine Inc. (NASDAQ: ONEW) (“OneWater” or the “Company”) today...
OneWater Marine Inc. Announces Fiscal First Quarter 2025 Earnings Release Date and Conference Call Information BUFORD, Georgia, Jan. 16, 2025 (GLOBE NEWSWIRE) -- OneWater Marine Inc. (NASDAQ: ONEW) (the “Company” or “OneWater”) announced today that it will release its first quarter 2025 financial results on Thursday, January 30th, 2025, before the market opens. Following the release, the Company’s management team will host a conference call to discuss the results at 8:30 a.m. Eastern Time that day. To access via phone, participants can use the dial in below: Event: OneWater Marine I...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 35,250 shares of Class A common stock and restricted stock units (RSUs) for 17,625 shares of Class A common stock to six new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in acc...
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. “This n...
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 – 16, 2025. The management team will also participate in one-on-one investor m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.